A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.

@article{Santoro2015ARM,
  title={A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.},
  author={Armando Santoro and Vittorio Gebbia and Tiziana Pressiani and Antonio Testa and Nicola Personeni and E Arrivas Bajardi and Paolo Foa and Angela Buonadonna and Katia Bruna Bencardino and Carlo Antonio Barone and Daris Ferrari and Alberto Zaniboni and Maria Chiara Tronconi and Giacomo Carten{\`i} and Michele Milella and Alessandro Comandone and Stefano Ferrari and Lorenza Rimassa},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2015},
  volume={26 3},
  pages={542-7}
}
BACKGROUND The management of biliary tract cancers (BTCs) is complex due to limited data on the optimal therapeutic approach. This phase II multicenter study evaluated the efficacy and tolerability of vandetanib monotherapy compared with vandetanib plus gemcitabine or gemcitabine plus placebo in patients with advanced BTC. PATIENTS AND METHODS Patients were randomized in a 1 : 1 : 1 ratio to three treatment groups: vandetanib 300 mg monotherapy (V), vandetanib 100 mg plus gemcitabine (V/G… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
14 Citations
32 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Vandetanib: first global approval

  • H Commander, G Whiteside, C. Perry
  • Drugs
  • 2011

Similar Papers

Loading similar papers…